Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026

Core Viewpoint - Can-Fite BioPharma Ltd. has signed a deal with Vetbiolix worth up to $325 million for the development of Piclidenoson, a treatment for osteoarthritis in dogs, with Vetbiolix funding all associated development costs [3][4]. Group 1: Company Overview - Can-Fite BioPharma Ltd. is a biotechnology company focused on developing proprietary small molecule drugs for oncological and inflammatory diseases [1][7]. - The company's lead drug candidate, Piclidenoson, has shown efficacy in a Phase III clinical study for psoriasis and is now being evaluated for canine osteoarthritis [6][7]. Group 2: Partnership and Financials - Vetbiolix has exercised its option for a full licensing agreement with Can-Fite, which includes upfront, milestone, and royalty payments potentially totaling $325 million over the next decade [3]. - The global canine osteoarthritis market is projected to reach approximately $3 billion by 2028, driven by increasing pet ownership and demand for effective therapies [4]. Group 3: Clinical Study Details - A Phase 2 clinical study is underway, involving 118 client-owned dogs with osteoarthritis, with primary and secondary endpoints focused on symptom severity, mobility, and pain assessment [2][5]. - Top-line results from the study are expected in the third quarter of 2026 [2]. Group 4: Product Information - Piclidenoson is a first-in-class A3 adenosine receptor agonist with a strong safety and efficacy profile, previously demonstrated in psoriasis treatment [6]. - Current treatment options for canine osteoarthritis are limited and primarily provide symptomatic relief, often with safety concerns [5]. Group 5: Vetbiolix Overview - Vetbiolix develops innovative veterinary products and has a pipeline of first-in-class oral small molecules targeting unmet medical needs in pets [9]. - The company focuses on clinical developments and aims to generate revenue through out-licensing and co-development deals within the veterinary pharmaceutical industry [9].